These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 23620452)
21. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029 [TBL] [Abstract][Full Text] [Related]
22. [Long-term results of rituximab-based salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma]. Wang XX; Huang HQ; Xia ZJ; Lin XB; Cai QQ; Gao Y; Lin ZX; Lin TY; Jiang WQ Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr; 30(4):867-70. PubMed ID: 20423868 [TBL] [Abstract][Full Text] [Related]
23. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study. Dilhuydy MS; Lamy T; Foussard C; Gressin R; Casassus P; Deconninck E; Le Maignan C; Damotte D; Milpied N; Biol Blood Marrow Transplant; 2010 May; 16(5):672-7. PubMed ID: 20045738 [TBL] [Abstract][Full Text] [Related]
24. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824 [TBL] [Abstract][Full Text] [Related]
25. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466 [TBL] [Abstract][Full Text] [Related]
26. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. Mounier N; Gisselbrecht C Curr Opin Oncol; 2011 Mar; 23(2):209-13. PubMed ID: 21169834 [TBL] [Abstract][Full Text] [Related]
27. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937 [TBL] [Abstract][Full Text] [Related]
28. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Smith SD; Bolwell BJ; Rybicki LA; Kang T; Dean R; Advani A; Thakkar S; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW Bone Marrow Transplant; 2011 Feb; 46(2):262-6. PubMed ID: 20479706 [TBL] [Abstract][Full Text] [Related]
29. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Dawar R; Hernandez-Ilizaliturri F Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454 [TBL] [Abstract][Full Text] [Related]
30. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484 [TBL] [Abstract][Full Text] [Related]
31. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654 [TBL] [Abstract][Full Text] [Related]
32. Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation. Manabe M; Hayashi Y; Yoshii Y; Mukai S; Sakamoto E; Kanashima H; Nakao T; Hayama T; Fukushima H; Inoue T; Yamane T; Teshima H Gan To Kagaku Ryoho; 2012 Nov; 39(11):1733-5. PubMed ID: 23152030 [TBL] [Abstract][Full Text] [Related]
33. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023 [TBL] [Abstract][Full Text] [Related]
34. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD; Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265 [TBL] [Abstract][Full Text] [Related]
36. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma. Shi YF; Zhou SJ; Sun L; Yu K; Chen Y Med Clin (Barc); 2020 Sep; 155(6):235-241. PubMed ID: 32173075 [TBL] [Abstract][Full Text] [Related]
37. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. Reddy NM; Greer JP; Morgan DS; Chen H; Park SI; Richards KL Leukemia; 2017 Jan; 31(1):241-244. PubMed ID: 27654851 [No Abstract] [Full Text] [Related]
38. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. Tsirigotis P; Dray L; Resnick IB; Ackerstein A; Gesundheit B; Elad S; Or R; Shapira MY Ann Hematol; 2010 Mar; 89(3):263-72. PubMed ID: 19693502 [TBL] [Abstract][Full Text] [Related]
39. Diffuse large B cell lymphoma: how can we cure more patients in 2012? Moskowitz C Best Pract Res Clin Haematol; 2012 Mar; 25(1):41-7. PubMed ID: 22409822 [TBL] [Abstract][Full Text] [Related]
40. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation. Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]